Munich Startup
rnhale

rnhale

RNhale develops inhaled RNA therapeutics for COPD and severe asthma. Our platform transforms RNA-loaded lipid nanoparticles into an inhalable dry powder, enabling direct, local delivery to the lungs. By addressing the key challeng...

Founded2023
Business ModelOther
IndustryLife Science
This content was machine translated.

About rnhale

RNhale develops inhaled RNA therapeutics for COPD and severe asthma. Our platform transforms RNA-loaded lipid nanoparticles into an inhalable dry powder, enabling direct, local delivery to the lungs. By addressing the key challenges of pulmonary RNA delivery, stability, deep lung deposition, and cellular uptake, our technology unlocks a more effective path for RNA-based therapies to reach their target. Our goal is to develop effective, locally-acting respiratory therapies that address disease at its molecular source. Our vision: to redefine the treatment of severe lung diseases.

Our Mission

We are bringing a new generation of efficient treatments to patients with COPD and asthma.

Our Vision

Redefining the therapy of severe lung diseases.

More like this

Discover more articles, startups, and events from the ecosystem

Rnhale: Inhalable RNA for new therapies
Interviews

Rnhale: Inhalable RNA for new therapies

23.03.26
4 Min.
€2.7 Million for Depotcharge
Deals

€2.7 Million for Depotcharge

21.09.26
4 Min.
Arcos Secures Millions in Funding for Integrated Security Infrastructure
Deals

Arcos Secures Millions in Funding for Integrated Security Infrastructure

21.09.26
3 Min.